The FDA cleared Orca Bio’s personalized Tregzi (T cell therapy) to reduce transplant-related complications in blood cancer patients undergoing stem cell transplants, the companies said. The approval targets the clinical tradeoff in transplant settings, where graft-versus-host disease and other long-term risks can limit outcomes. Orca Bio positioned Tregzi around regulatory T cells (Tregs) as an alternative approach to traditional donor selection, aiming to improve survival without adding the same degree of chronic complications. The decision also puts pressure on other transplant-complication strategies, particularly those seeking to reduce GVHD burden while preserving curative potential. For biotech developers, the move underscores continued FDA willingness to act on engineered immune-cell strategies that can shift risk profiles in transplantation rather than only addressing disease control.